Stock 002393 TIANJIN LISHENG PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Tianjin Lisheng Pharmaceutical Co.,Ltd.

Tianjin Lisheng Pharmaceutical Co.,Ltd. Stock price

Equities

002393

CNE100000NJ9

Pharmaceuticals

End-of-day quote Shenzhen Stock Exchange
Other stock markets
 06:00:00 2023-11-30 pm EST 		Intraday chart for Tianjin Lisheng Pharmaceutical Co.,Ltd. 5-day change 1st Jan Change
27.58 CNY -1.08% +0.47% +29.54%
Nov. 10 Tianjin Development to Vote Dec. 5 on Lisheng Pharma's Sale of Tianjin Pharmaceutical Finance Stake MT
Oct. 29 Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Financials

Sales 2022 1,147 M 161 M Sales 2023 * - Capitalization 3,917 M 549 M
Net income 2022 93.00 M 13.03 M Net income 2023 * - EV / Sales 2022
1,72x
Net cash position 2022 1,949 M 273 M Net cash position 2023 * - 0 EV / Sales 2023 * -
P/E ratio 2022
41,7x
P/E ratio 2023 *
Employees 1,374
Yield 2022
1,41%
Yield 2023 *
-
Free-Float 44.77%
More Fundamentals * Assessed data

Chart Tianjin Lisheng Pharmaceutical Co.,Ltd.

Dynamic Chart

Latest news about Tianjin Lisheng Pharmaceutical Co.,Ltd.

Tianjin Development to Vote Dec. 5 on Lisheng Pharma's Sale of Tianjin Pharmaceutical Finance Stake MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. for CNY 87.8 million. CI
Lisheng Pharmaceutical's H1 Attributable Profit Jumps MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Lisheng Pharmaceutical Subscribes for 20 Million Yuan Wealth Management Product MT
Lisheng Pharma to Receive 247.9 Million Yuan for Relocation MT
Lisheng Pharmaceutical Eyes 247.9 Million Yuan from Potential Land Resumption Deal MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date Is 30 June 2023 CI
Tianjin Lisheng Pharma Gets Nod For Febuxostat Active Pharma Ingredient in China MT
Lisheng Pharma Unit's Drug Passes Regulatory Evaluation MT
Tianjin Lisheng Pharmaceutical's Q1 Attributable Profit Increases MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Lisheng Pharmaceutical's Audited 2022 Profit Marginally Higher Than Unaudited Results MT
Tianjin Lisheng Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Year 2022 CI
More news

Quotes and Performance

1 day-1.08%
1 week+0.47%
Current month-1.08%
1 month+1.47%
3 months+10.72%
6 months+13.17%
Current year+29.54%
More quotes

Highs and lows

1 week
26.88
Extreme 26.88
28.30
1 month
26.08
Extreme 26.08
28.30
Current year
21.40
Extreme 21.4
28.80
1 year
21.06
Extreme 21.06
28.80
3 years
16.46
Extreme 16.46
28.80
5 years
16.46
Extreme 16.46
32.71
10 years
16.46
Extreme 16.46
59.98
More quotes

Managers and Directors - Tianjin Lisheng Pharmaceutical Co.,Ltd.

Managers TitleAgeSince
Fu Jun Wang CEO
 Chief Executive Officer 56 2017
Jia Ying Wang DFI
 Director of Finance/CFO - -
Zi Long Liu IRC
 Investor Relations Contact - -
Members of the board TitleAgeSince
Fu Jun Wang CEO
 Chief Executive Officer 56 2017
Dao Qing Xu CHM
 Chairman 61 -
Qi Fei Zhuang BRD
 Director/Board Member 51 -
More insiders

ETFs positioned on Tianjin Lisheng Pharmaceutical Co.,Ltd.

Name Weight AuM 1st Jan change Investor Rating
VANGUARD FTSE EMERGING MARKETS ETF - USD ETF Vanguard FTSE Emerging Markets ETF - USD
0.00% 64,346 M€ +4.67%
VANGUARD FTSE EMERGING MARKETS SHARES ETF - AUD ETF Vanguard FTSE Emerging Markets Shares ETF - AUD
0.00% 422 M€ +4.19% -
VANGUARD FTSE EMERGING MARKETS ALL CAP INDEX ETF - CAD ETF Vanguard FTSE Emerging Markets All Cap Index ETF - CAD
0.00% 1,083 M€ +4.26% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 38 M€ +0.96% -
RPAR RISK PARITY ETF - USD ETF RPAR Risk Parity ETF - USD
0.00% 775 M€ -0.81% -
More ETFs positioned on Tianjin Lisheng Pharmaceutical Co.,Ltd.

Quotes

Date Price Change Volume
23-12-01 27.58 -1.08% 2,244,000
23-11-30 27.88 +1.60% 1,860,589
23-11-29 27.44 -0.15% 1,618,600
23-11-28 27.48 +0.11% 2,158,198
23-11-27 27.45 0.00% 3,838,547

End-of-day quote Shenzhen Stock Exchange, December 30, 2023

More quotes

Company Profile

Tianjin Lisheng Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of chemical drugs. The Company's major products are tablets, hard capsules, pills, free-dry powder injections, water injections and raw drugs, including drugs for cardio and cerebral vascular systems, anti-infection drugs and hormone drugs, among others. It distributes its products mainly within domestic markets.
Sector
Pharmaceuticals
Calendar
2024-03-21 - Q4 2023 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
TIANJIN LISHENG PHARMACEUTICAL CO.,LTD. Stock Tianjin Lisheng Pharmaceutical Co.,Ltd.
+29.54% 705 M $
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+32.96% 21 099 M $
SANDOZ GROUP AG Stock Sandoz Group AG
0.00% 12 720 M $
CIPLA LIMITED Stock Cipla Limited
+12.06% 11 688 M $
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-12.16% 8 801 M $
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+52.33% 7 775 M $
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6 788 M $
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5 726 M $
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Stock Shenzhen Salubris Pharmaceuticals Co., Ltd.
+0.79% 5 062 M $
TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. Stock Taisho Pharmaceutical Holdings Co., Ltd.
+49.91% 4 841 M $
Generic Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Tianjin Lisheng Pharmaceutical Co.,Ltd. - Shenzhen Stock Exchange
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer